Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes. By Brendan Borrell When Stephane Castel first ...

A rooftop deck at Variant Bio’s Seattle offices have a view of the city’s landmark Space Needle. (Cory Parris Photo) Variant Bio today announced a partnership with Novo Nordisk for disease ...

As a result, there is still an unmet need in this space," said David Moller, Chief Scientific Officer at Variant Bio. "We hope that a deeper understanding of the relationships between genetic ...

Commercial terms include an upfront payment and additional near-term R&D funding totaling up to $50 million, plus potential option and milestone payments SEATTLE, Jan. 7, 2025 /PRNewswire/ -- Variant ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from diverse populations.

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populations.